Published

Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Cureus
Date: 2026-09-13
Source: Europe PMC
DOI: 10.7759/cureus.116178
PubMed: 42733721

Authors

Raffa RB.

Watch author

Derived topics and classifications

psilocybin Depression Addiction Mechanism of Action Review Article Treatment-Resistant Depression Drug Interactions Genomics Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.2026-09-13

Related papers

Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.Frontiers in neuroscience · 2026-01-01